|
Apr 1
|
5 FDA decisions to watch in the second quarter
|
|
Mar 21
|
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
|
|
Mar 19
|
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
|
|
Mar 15
|
Geron, Madrigal Pharmaceuticals jump on good news from FDA
|
|
Mar 15
|
Stocks to Watch Friday: Adobe, Ulta, Fisker
|
|
Mar 15
|
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
|
|
Mar 14
|
Geron Stock Is Soaring After Hours: What's Going On?
|
|
Mar 14
|
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
|
|
Mar 14
|
UPDATE 3-Geron's blood disorder drug gets FDA advisers' backing
|
|
Mar 13
|
Implied Volatility Surging for Geron (GERN) Stock Options
|
|
Mar 12
|
UPDATE 3-US FDA staff raises concerns on Geron's blood disorder drug
|
|
Mar 1
|
Geron Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Feb 29
|
Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript
|
|
Feb 28
|
Geron (GERN) Q4 2023 Earnings Call Transcript
|
|
Feb 28
|
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
|
|
Jan 12
|
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
|
|
Dec 6
|
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
|
|
Dec 4
|
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
|
|
Nov 28
|
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
|
|
Sep 29
|
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
|